As experts in creative healthcare communications, we make complex information understandable, accessible and actionable for patients.
Everything we do is underpinned by the patient voice, gathered through advocacy group partnerships, focus groups, and many other tactics. This feeds into what we create, and how we share it.
We’re incredibly proud of our success stories to date, including:
New ways to empower dialogue between patients and healthcare teams
Working with patients with accessibility barriers to create materials that meet their needs
Improving the informed consent process to ensure patients are truly informed during clinical trials
Helping patients recognise, report, and cope with treatment side effects
In our V2V case study, we’ll share how we worked with patients to co-create a suite of materials that would help them and their loved ones understand a new type of cancer therapy, and make treatment choices that were right for them.
We’d love to hear your thoughts!
Rate this presentation
Sponsored by














Great to see a global approach. Is / was the tool kit able to be adapted for specifical local needs / requirements?
I'm longing to know 'who' the pharma sponsor is so I can congratulate them for sponsoring this important health education and literacy work. Truly this is an 'all in' approach. Even as a Medical Biochemist with 25y working in pharma, all info about immunotherapy is incredibly complex so to align so many patients from so many different countries and create resources that work for the many not the few is admirable. Great work.
Another excellent example of a pharma company truly listening, not just to patients but also to those who care for them, including healthcare professionals. The development of educational materials created with the patient community is a clear step forwards, has this translated into a greater acceptance of IO therapies by patients / carers? If that behaviour change could be included as a 'look ahead' it is likely to successfully illustrate the importance of this work to others. The biggest challenge is going to be pharma company commitment (i.e. people and budget) to maintain and build on this partnership and to continue to address the needs of their patient community.